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 INTRODUCTION 
 
 Medical abortion is a safe effective means of terminating a 
pregnancy and has been shown to be widely acceptable in both 
developed and developing countries in all world regions. This 
method uses pharmacological agents such as mifepristone and 
misoprostol to expel the contents of the uterus.  Used in combination 
these medications stimulate uterine contractions and causes 
expulsion of the pregnancy. 
 
 Misoprostol alone may be useful where mifepristone is not 
available.  The use of Misoprostol alone at the community and 
primary care levels has the potential to significantly increase, 
women’s assess to safe abortion. 
 Considerable saving in resources can be made if routine 
curettage can be avoided and a medical rather than surgical abortion 
adopted. 
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AIM OF THE STUDY 
 
1. To evaluate the efficacy of single  dose 800 μg of vaginal 
misoprostol in I trimester pregnancy termination. 
2. To critically evaluate the percentage of patients needing 
multiple doses 
3. To study and evaluate the failure rate, complications and 
side effects with Misoprostol usage. 
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REVIEW OF LITERATURE 
 
 Our primary objective is to determine the efficacy of single 
dose of vaginal misoprostol 800 μg in complete expulsion of 
products of conception. 
 Following are the studies conducted by various authors about 
the efficacy of vaginal misoprostol 800 μg in first trimester 
pregnancy termination. 
1. Salakos et al – Department of obstetrics and Gynaecology, 
University of Athens, aretoreion hospital, Greece, Dec 2005. 
 The objective of the study was to evaluate the efficacy and 
safety of 800 μg of misoprostol every 12 hrs for a period of 36 hrs 
for pharmacologic abortion.  A group of 162 volunteer women with 
gestational age between 5.0 and 6.3 weeks received Misoprostol. 
Outcome measures included :  
Successful abortion (complete abortion without requiring 
surgery) side effects and a decrease in hemoglobin, mean time of 
vaginal bleeding, mean expulsion time and mean time of returning 
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menses.  Complete abortion occurred in 148 of 162 ((91% , 95% 
confidence interval 87.95) patients. 
 The mean decrease in hemoglobin was statistically significant 
(p=0.001). Vaginal bleeding lasted 8.0 + 3.2 days, spotting 8.0 + 3.5 
days and total bleeding 16 + 4.0 days.  The mean expulsion time was 
8.5 + 4.0 hrs. 
 According to the observed outcomes 800 μg of misoprostol 
vaginally could be a valid method to terminate pregnancies upto 9 
weeks of gestation. 
2. Kovavisaraels F. Jammansiri C. Sep 2005, Department of 
Obstetrics and Gynaecology. Rajavithi Hospital, Ministry of public 
health, Bangkok. 
 To compare the respective effectiveness and safety of 600 
micrograms and 800 micrograms of intravaginal misoprostol for 
complete abortion in cases of early pregnancy failure (Occuring in 
the first 12 weeks) 
 A total of 114 women with diagnosis of early pregnancy failure 
was taken on to the study. 
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 The rate of complete abortion with in 24hrs was significantly 
higher in the group that received 800μg of misoprostol (78.4%) than 
on the other group (45.5%).  There was no significant difference in 
side effects. 
3. Cartoneck JL et al, Hospital Docante Gineco –obstetrics 
Fusesio Hernandez (Materwidad obnera) Lindd de in Habana Cuba 
March 1999. 
 The objective of this study was to demonstrate the 
effectiveness and safety of self administration of misoprostol every 
12 hrs without the need of post expulsion systematic curettage in late 
first trimester abortion (10-13 wks gestation) A group of 180 women  
with gestations from 64 to 91 days.  Self administered 800 μg  of 
vaginal misoprostol every 12 hrs for a maximum of three doses 
without performing post expulsion systematic preventive curettage. 
Successful abortion occurred in 153/180 (85%) subjects. 
 The high degree of acceptability, its efficacy and the fact that 
post abortion systematic curettage was not needed make misoprostol, 
a suitable alternative to the commonly available method for 
termination of pregnancy at 10-13 wks gestation. 
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4.   Carbonell JL, et al, - the use of misoprostol for abortion at < or = 
9 wks gestation. Eur. J. Corikacept Reprod.  Health Care 1997. 
5. Ngai Sh, Tang YS, Chan YM, HO PC Vaginal misoprostol 
alone for medical abortion up to 9 wks of gestation : Efficacy and 
acceptability : Hum Reprod. 2000. 
6.  In a study by creiwin et al (1997) Comparison was made between 
400 μg oral misoprostol and 800 μg vaginal misoprostol for medical 
evacuation of early failed pregnancy with an embryo of 15 to 14 mm 
with no cardiac activity of an empty irregular gestational sac of 
atleast 16 mm diameter.  The dose was repeated after 24 hrs in case 
of failure of expulsion. 
 The rate of complete expulsion with in 48 hrs was 25% in oral 
misoprstol  and 88% percent in vaginal misoprostol group. 
7. Zalanyi 1998 and Herabontya et al, 1997. 
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I Trimester Abortion 
 Abortion is the termination of pregnancy either spontaneously 
or intentionally before the foetus develop sufficiently to survive.  
 By convention, abortion is usually defined as pregnancy 
termination prior to 20 weeks gestation or less than 500gm birth 
weight. 
 More than 80 percent of abortion occur in the first 12 weeks of 
pregnancy and atleast half result from chromosomal anomalies. After 
the Ist trimester both the abortion rate and the incidence of 
chromosomal anomalies decrease. 
Etiology : 
 The exact mechanism responsible for abortion are not always 
apparent but in the first 3 months of pregnancy, death of the embryo 
or fetus nearly always precedes spontaneous expulsion of the ovum.  
For this reason, finding the cause of early abortion involves 
ascertaining the cause of foetal death. 
 Foetal factors 
 Maternal factors 
 Paternal factors 
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Foetal factors : 
 Abnormal zygotic development 
 Aneuploid abortion 
 Euploid abortion 
Maternal factors : 
¾ Infection 
¾ Chronic debilitating diseases 
¾ Endocrine abnormalities 
  Hypothyroidism 
  Diabetes mellitus 
  Progesterone deficiency 
¾ Nutritional deficiency 
¾ Drugs and environmental factors 
  Tobacco 
  Alcohol 
  Caffeine 
  Radiation 
  Contraceptives  
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• Environmental toxins 
 Arsenic 
 Lead 
 Formaldehyde 
 Benzene 
 Ethyl oxide 
¾ Immunological factors 
Paternal factors : 
 Chromosomal abnormalities in sperm have been associated 
with abortion. 
Categories of abortion   Spontaneous  
      Induced 
1. Threatened abortion 
2. Inevitable abortion 
3. Complete and incomplete abortion 
4. Missed abortion 
5. Recurrent abortion 
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SIGNS AND SYMPTOMS 
 The signs and symptoms of abortion are 
1. Pain due to uterine contraction 
2. Haemorrhage as the result of separation of the ovum 
3. Dilatation of the cervix due to uterine contraction 
4. Expulsion of a part of or the entire ovum 
 
The patient generally gives a history of amenorrhoea followed by 
more or less severe pain in the lower abdomen and back 
accompanied by vaginal bleeding.  The extent of the haemorrhage 
varies and may some times be so profuse as to cause severe 
collapse.  Usually however the haemorrhage continues for some 
days, the quantity varying from day to day. The pain may be 
severe, but is never so great as in cases of ruptured ectopic 
gestation. 
 Where pain and haemorrhage are present dilatation of the 
cervical canal may be present and occasionally a portion or the 
whole of the uterine contents may be expelled. 
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 Depending upon the signs and symptoms the following types 
of abortions may be recognized. 
1.  Threatened Abortion : 
 In this condition, after a period of amenorrhoea, the patient 
complains of slight colicky pains in the lower abdomen associated 
perhaps with back ache,  frequency of micturition and slight 
bleeding per vaginum.  If a careful bimanual examination is done 
the cervix will be found softened, the uterus enlarged and more or 
less globular the size depending on the period of pregnancy.  The 
OS is generally closed or may in some cases be slightly patulous 
when there is no actual sign suggestive of death or expulsion of 
portion of the ovum, the condition is known as threatened 
abortion. 
2. Inevitable or incomplete abortion : 
 This term denotes that the ovum has practically separated from 
the uterine wall and is therefore dead and bound to be expelled.  
In such cases, the pain is more severe, the bleeding more profuse, 
the cervix is dilated and occasionally a portion of the ovum may 
be felt protruding through the cervical canal.  When only a part of 
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the products of conception has been expelled, it is termed 
incomplete abortion. 
3. Complete Abortion : 
 This term is used when the entire ovum has been expelled.  
Once this has occurred the pain subsides and bleeding decreases 
and may have stopped by the time the patient is seen.  The uterus 
is empty and is accordingly smaller in size than the period of 
amenorrhoea would suggest and the cervical canal may be closed, 
as it contracts very rapidly after the complete expulsion of the 
uterine contents. 
4.  Missed Abortion : 
 In this condition, symptoms of abortion occur but subside later  
without any part of the ovum being expelled.  The ovum dies but 
is retained in the uterus.  The patient gradually recover from the 
attack of pain and the vaginal haemorrhage subsides.  The 
haemorrhage that has occurred in utero forms a clot round the 
dead ovum and changes takes place subsequently in and around 
the ovum. In the early stages, the clotted blood with the ovum 
in it presents a peculiar condition which is known as blood mole.  
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Later when the blood clot becomes organized the appearance 
changes.  In the course of few weeks the whole of the uterine 
contents are changed into a dark red or brownish stagy mass 
known as carneous mole.  Occasionally in these changes owing to 
the formation of hematoma of varying sizes between the amniotic 
and the chorionic membranes, a further change takes place 
resulting in the formation of what is known as tuberose mole.  
Where a mole has developed, the foetus may not be present or 
even if it does exist, it is of very small size.  This is due to the fact 
that in the large majority of cases the malformation takes place in 
the early weeks of pregnancy.  Consequent on the long lapse of 
time before the mole is expelled, the foetus may be absorbed or in 
some cases it may be found as a rudimentary vestigial structure.  
Where mole formation has taken place the amemorrhoea may 
persist but none of the progressive signs of pregnancy are present.  
Thus the uterus does not continue to enlarge in size.  The breast 
changes cease the patients may not feel any of the subjective 
symptoms of pregnancy and generally presents herself for the 
persistent amenorrhoea.  A bimanual examination will reveal that 
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the uterus though enlarged never corresponds to the period of 
amenorrhoea and is smaller. 
 The cervical softening does not persist and the uterus itself 
doesnot have the soft feel of a normal pregnancy. If a pregnancy 
test is done at the stage the result will be negative. 
Febrile abortion : 
 In febrile abortion, signs and symptoms of abortion exist, with 
a rise of temperature.   
 This may be due to two distinct factors.   
a) In one set of cases, the rise of temperature may precede the 
signs and symptom of abortion and may be the causative factor 
or atleast one of the causative factors.  In such cases the 
temperature is the cause and not the result of abortion. 
b) In other cases, the rise in temperature may be due to sepsis, and 
the patient besides presenting the usual symptoms of pain and 
haemorrhage, will have an offensive discharge per vaginum. 
This is called septic abortion. 
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Therapeutic Abortion : 
 Where abortion is induced as a therapeutic measure for the 
sake of the mother it is spoken of as therapeutic abortion. 
 In modern obstetrics, there are a few indications for therapeutic 
abortion. 
 Cardiac disease (Grade III and IV) and decompensation in a 
previous pregnancy and justifiable indication for termination of 
progress in the first trimester.  It is necessary that optimum 
compensation be established prior to termination. 
 Epilepsy and other forms of psychosis in the mother who had a 
number of children may justify a therapeutic abortion. 
 Intractable hyperemesis gravidarum will necessitate 
termination of pregnancy. 
 If the mother contracts German measles in the early weeks of 
pregnancy, induction of abortion is advocated by some on the plea of 
a malformed foetus being born.   
 Chronic glomerulonephritis, malignant hypertension. 
Pregnancy following radical mastectomy for carcinoma of the breast 
are other indications. 
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 In India, abortion is legalized by liberal act called Medical 
termination of pregnancy (MTP) act. 
 Chromosomal and enzyme abnormalities have now been 
identified as factors responsible for the transmission of certain 
inherited disorders. Some of these disorders may also be sex linked.  
It is possible to determine by examination of the liquor amni whether 
the intrauterine foetus will be affected or not. 
 If the investigations yield a positive result, it is now the 
practice to induce abortion. Sex linked diseases like hemophilia, 
progressive muscular atrophy and chromosomal abnormalities 
resulting in various genetically induced diseases as also iatrogenic 
disorders can now be diagnosed early and the therapeutic abortion 
performed. 
 
Diagnosis : 
 Uterine abortion has to be differentiated from 
1. Functional menstrual disturbances 
2. Ectopic gestation 
3. Hydatiform mole 
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In functional menstrual disturbances the woman has irregular 
menstruation there may be amenorrhoea for periods varying from 
six to twelve weeks but the history is generally suggestive.  A 
profuse bleeding occurring at the end of that period may suggest 
the possibilities of an abortion, but a careful bimanual 
examination will reveal the absence of signs of pregnancy.  In 
case of doubt pregnancy test and ultrasonography will helpful. 
 Difficulty is often encountered in differentiating uterine 
abortion with a retroverted gravid uterus from as un ruptured 
ectopic gestation or tubal abortion with a pelvic hematocele.  In 
the two latter conditions, there may be history of a short period of 
amenorrhoea with occasional attacks of colicky pain in the lower 
abdomen and vaginal bleeding which is seldom profuse.  Vaginal 
examination revealing a uterus smaller in size than the period of 
amenorrhoea would warrant  an extremely tender mass in one or 
other of the fornices or the dounglas pouch separate from the 
uterus.  Blood can most often be aspirated  from the mass through 
the posterior fornix thus helping to clinch the diagnosis. 
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 In vesicular mole, the uterus is often bigger than the 
corresponding period of amenorrhoea. The pregnancy test is 
positive in high dilutions and examination of any products passed 
per vaginum may reveal vesicles. 
 
Methods of first Trimester pregnancy termination 
Medical Method : 
1. Prostaglandin 
2. Anti-progesterone – RU 486 ( Mifepristone and 
epostaine) 
3. Methotrexate – intramuscular and oral 
 
Surgical Methods : 
 Cervical dilatation followed by uterine evacuation 
  Curettage 
  Vaccum aspiration (suction curettage) 
  Dilatation and evacuation (D & E) 
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TECHINIQUES: 
A. Vacuum aspiration or suction curettage or suction evacuation 
The procedure of vacuum aspiration (VA) is described in two 
parts; dilatation and  aspiration. 
Dilatation: 
1. The patient comes to the table after passing urine and is put in 
the lithotomy position. Shaving is not essential.  
Catheterization is not done. Bimanual examination is 
performed routinely to note the size and position of the uterus.  
If the uterus is retroverted, it is made anteverted wherever  
possible without producing much pain. 
2. The vulva and vagina are cleaned with antiseptic solution.  A 
posterior vaginal speculum is introduced.  The cervix is painted 
with an antiseptic solution like 5-10% povidone –iodine.  
Drawing about 20 ml of 1% lignocaine with adrenaline in a 
syringe, 2 ml is injected into the cervix at the 12 o’clock 
position.  The cervix is caught with a non-traumatic vulsellum 
(Jacob’s tenaculum or strong  Allis’ forceps) 8 ml of lignocaine 
(Xylocaine ) with 1:300,000 epinephrine or adrenaline  is 
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injected at the 4 0’ clock and 8 o ‘ clock positions 2 mm 
underneath the mucosa at the cervicovaginal junction, 
producing blanching of the mucosa.  Before pushing 
lignocaine, the piston is withdrawn to make sure that vessels 
have not been punctured.  After waiting for 3-5 minutes, a 
uterine sound is passed gently to note the position and measure 
the size of the uterine cavity.  It must not be pushed hard when 
resistance is met at the fundus, otherwise there will be 
perforation.       
3. At this stage ergometrine  0.5 mg or methylergonovine 
(Methergine) 0.20 mg is given intravenously; instead of 
ergometrine, oxytocin 5 units may be injected intramuscularly.  
It reduces bleeding, particularly in late first trimester 
pregnancy cases, and hardens the uterus and lessens the chance 
of perforation.  It does not produce any difficulty during 
dilatation.  
4. The length of the uterine cavity, as measured by the sound, 
corresponds with the age of gestation from the first day of the 
last menstrual period, and on this measurement the cannula size 
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is chosen: e.g. 8weeks of pregnancy = 8 cm uterine depth = 8 
mm cannula, 10 weeks =10 cm uterine depth =10mm cannula. 
If cervical resistance is too great, a cannula of 1 or 2 mm 
smaller size may be used, but the need for forceps and curette 
will be increased. To avoid cervical injury the cervix is held 
steadily with the forceps and dilators are introduced with 
steady force, keeping the index finger on the dilator in such a 
way that the top part is short of the uterine length, the dilator 
being held with the whole of the hand instead of in a pen-
holding fashion. This technique also prevents uterine 
perforation in the case the dilator slips in suddenly, as happens 
sometimes. When there is much resistance, it is helpful to leave 
each dilator in place for 30-60 seconds. It should be 
remembered that it is the internal os which needs to be dilated 
and not the external os. 
Aspiration  
5. The cannula size is chosen according to the length of the 
uterine cavity and is fitted with the suction apparatus. The set 
should be tested for its air tightness before the procedure is 
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started. The cannula is gently introduced up to the fundus and 
the machine is started. When the vacuum is created, the 
cannula is moved against the uterine wall from above 
downwards to the level of the internal os repeatedly in a 
clockwise manner for 360 degrees, then in an anticlockwise 
manner up to the starting position os as to evacuate the 
contents and soft curette the uterus; the end point of curettage 
will be the uterine cry- this is a grating sensation covering the 
whole of the endometrial cavity.  
6.  Check curettage with a sharp curette is done routinely by most 
physicians so as to remove leftover fetal products, if any, but 
curettage should not be done too rigorously as it may produce 
synechiae and permanent oligomenorrhoea or amenorrhoea. 
7. Ergometrine  0.5 mg or methylergonovine (Methergine) 
0.20mg us given intramuscularly as a routine, irrespective of 
earlier administration of the ecbolics. Bleeding is checked. The 
tenaculum forceps and vaginal speculum are withdrawn. 
Bimanual examination is repeated so as to be sure that the 
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uterus is hard and smaller in size than prior to the procedure; 
this step ensures evacuation of the uterus. 
8. The materials removed during the operation are placed in a 
glass container and carefully examined to see if the volume and 
nature of the matter is consistent with the gestational age. 
Some of these are materials placed in a glass container 
containing water, particularly when the tissues are small in 
amount, to ascertain fetal products. The fresh placental tissues 
always float water. In cases of doubt the tissues should be sent 
for histological examination. Routine pathological examination 
is unnecessary and is not done. 
If little or no tissue is obtained, the physician should think 
of the possibility of : (1) failure to interrupt the pregnancy,  (2) 
non-pregnancy, (3) ectopic pregnancy, (4) incomplete abortion 
(5) very early intrauterine pregnancy, (6) false passage, or (7) 
uterine perforation. These cases should be watched and 
followed up carefully. In practice, however, this step is often 
not followed.  
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9. The patient is watched in a side room for ½ - 2 hrs depending 
upon the case and is then discharged with the necessary 
directions. 
10. If laminaria tents have been introduced, after cleaning the 
vulva the tents are removed first by means of a sponge-holding 
clamp forceps. Dilatation is then performed. 
B. Dilatation and evacuation(D&E) 
This operation, also called dilatation and curettage 
(D&E), has two parts. The first part of dilatation is done in the 
same way as in vacuum aspiration following steps number 1 to 
4. Ergometrine 0.5 mg is given intravenously as a routine. 
Ovum forceps of different sizes are available for the purpose; 
very small size for cavity length below 7 cm, medium size for 
cavity length 8-9 cm and large size for cavity length of above 9 
cm are chosen after fixing the uterus with a tenaculum forceps. 
The ovum forceps is introduced in a closed position, opened  
inside the uterine cavity and  rotated for 90 degrees in 
clockwise or anticlockwise manner, closed so as to hold fetal 
tissue tightly, and taken out as much as possible of the fetal 
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products. Curettage is then done by a sharp or blunt curette. 
The author prefers to use a sharp curette in early weeks of 
pregnancy and after the uterus is contracted towards the end of 
the operation in later weeks of first trimester pregnancy. 
Curettage must not be done too rigorously. Steps 7 to 10 as in 
vacuum aspiration are then followed. 
Postoperative care and follow-up  
Administration of routine antibiotic following VA or 
D&E is debatable. However, it should be given when local 
infection is present, where operations are not done with proper 
aseptic care under ideal circumstances, or where the procedures 
have involved more time or bleeding. Before discharge, the 
patient should be informed that she can fall pregnant even after 
7-14 days. As such contraceptive measures should be 
undertaken from the very beginning. 
 Intrauterine device can be introduced at the time of D&E 
if infection is not present or likely, OC should be started within 
one week, barrier contraceptives should be used whenever 
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sexual intercourse is resumed and ligation of tubes can be 
performed at the time of abortion (PAI,1993).  
 The patient is advised to have normal activities except 
intercourse for the next 10-14 days, and to revisit the physician 
after 2 weeks for routine check-up, or earlier in case she 
develops any of the following features: (1) acute pain in lower 
abdomen, (2) rise of temperature, (3) persistent pain for more 
than 7 days, (4) heavy or persistent fresh bleeding, or (5) 
persistent pregnancy symptoms. 
 In cases with acute pain, ectopic or acute pelvic infection 
should be suspected and appropriate treatment must be 
immediately started after diagnosis. In cases with other 
features, vacuum aspiration and curettage are often repeated 
with or without antibiotics. 
Complications and their remedies 
 Complications of VA and D&E depend a lot upon several 
factors of which the most important ones are operator’s skill, 
available  facilities and gestational age; others are type of 
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anaesthesia and instrumentation, patient’s age, parity, 
socioeconomic status and pre-existing diseases. 
 Compared to other surgical operations legally induced 
first trimester pregnancy termination is remarkably safe, the 
major complications rate being less than 1 in 100 procedures 
(Grimes et al, 1977; Lewit, 1972) the risk of dying from these 
procedures is eleven times lower than the risk of dying from 
pregnancy and childbirth (Cates et al, 1979). Major 
complications following D&E are twice as frequent as with VA 
(PAI, 1993). 
Uterine haemorrhage. 
It occurs in 1-4% cases although blood transfusions are 
required in only 0.6 / 1000 –abortions. Haemorrhage happens 
more often with advanced gestational age, when D&E is 
performed instead of VA, and when general anaesthesia is used 
instead of local anaesthesia. It can be reduced to a great extent 
by the concomitant use of oxytocic drugs during the procedure 
and by prior use of laminaria tent. 
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Pelvic infection.  
It ranges from 0.1 -1.5 %. It is due to incomplete 
evacuation and improper aseptic technique. The incidence can 
be reduced to a great extent by prophylactic use of antibiotic. 
Cervical injury.  
This complication occurs in 0.01-1% cases. It happens 
more often with D&E than with VA, in advanced gestational 
age and in nulliparous women. It can be minimized to a great 
extent by the use to Hawkins-Ambler or Pratt dilators instead 
of Hegar dilators, and by preoperative cervical priming and 
dilatation by the use of laminaria tents. 
Uterine perforation.  
This is the most dangerous complication, but fortunately 
it happens very rarely in0.1-0.28% cases. Nulliparous patients 
in whom laminaria tent had not been used had a 15 fold higher 
risk of cervical injury than multiparous women, according to a 
Baltimore study (King, 1977). The incidence of perforation can 
be minimized by using the proper technique as detailed earlier, 
by the use of Hawkins-Ambler or Pratt dilators and the use of 
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laminaria tent. When perforation occurs or is suspected, the 
patient should be kept under observation and antibiotics should 
be started. Usually she can be discharged in 24 hrs time. If 
there is strong suspicion or actual diagnosis of injury to the 
intestines or omentum, or if haemorrhage occurs, laparotomy 
should be performed followed by necessary steps. 
Retained products.  
Incomplete abortion happens in 24% of the cases. The 
incidence is reduced by performing check curettage following 
VA and by following proper techniques with the help of well- 
trained personnel. These cases need repeat D&E and 
antibiotics. 
Continuation of pregnancy.  
VA fails in about 1% cases; failure is more within two 
weeks of amenorrhoea.Routine follow-up, and reporting of 
patients if pregnancy symptoms continue or amenorrhorea 
continues for more than 4 weeks, will help diagnosis. Repeat 
VA and / or D&E is needed. 
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  Maternal mortality and morbidity.  
Cases et al (1979) and Lewit (1972) found that the 
morbidity rate is lowest between 7 and 8 weeks of pregnancy, 
after which the risk of complications rises by about 15-30% for 
each week of delay. 
 Mortality from VA and D&C is very rare, being 1.3 per 
100,00 procedures in the large JPSA/CDC study in the USA 
from 1972-1977 (Cates et al, 1979); at 8 weeks’ gestation or 
earlier, the death rate was 0.5/100,000 abortions; at 9-10 weeks 
1.6, and at 11-12 weeks 3.3. Thus the risk of dying increased 
by 50% per week as the gestational age increased. 
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Menstrual regulation  : 
 Menstrual regulation consists of aspiration of contents of 
uterine cavity by means of a plastic cannula (karman’s cannula) and 
a plastic 50 ml syringe capable of creating a vaccum of over 60 cm 
Hg. It is carried out effectively with in 42 day of the beginning of the 
last menstrual period (LMP).  A paracervical local anaesthetic block 
or preoperative sedative alone usually, suffices but some times in our 
apprehenside patient, general anaesthesia with intravenous 
thiopentone sodium may be necessary.  The procedure can be 
performed in an office set up, out patient clinic or other day care 
centre.  Since 1970, this method has been extensively evaluated and 
found to be efficient, safe and easy to use in terminating early 
pregnancy.   
 It is a good practice to examine the products of conception.  
The occasional complications encountered include failure to evaluate 
leading to continuation of pregnancy, incomplete evacuation, 
haemorrhage, cervical laceration, perforation, infection and 
anaesthetic complication. 
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Features of Medical and Surgical Abortion 
 Medical Abortion Surgical Abortion 
1. Usually avoids invasive 
procedure 
Invasive procedure 
2.  Usually avoids anaesthesia Sedation used if desired 
3. Regular two or more visits Usually requires one visit 
4. Days to week to complete Complete in a predictable period
5. Available during early 
pregnancy 
Available during early 
pregnancy 
6. High success rate ( 95%) High success rate (99%) 
7. Regular follow up to ensure 
completion of abortion 
Doesn’t require follow up in all 
cases 
8. Requires patient participation 
through out  multi step progress 
Requires participation in a single 
step process 
 
 From the American College of Obstetrics and Gynaecology 
2001. 
Contraindication of Medical abortion : 
 Allergy 
 Intra uterine disease 
 Severe anaemia 
 Coagulopathy  
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 Active liver disease 
 Cardiovascular disease 
 Uncontrolled seizure disorder 
 Adrenal diseases 
 On glucorticoid therapy 
From American College Obstetrics and Gynaecology 2001. 
 In this study, after counselling and making an informed 
decision to terminate a pregnancy with medications and a physical 
exam to ensure that the woman is medically eligible for medical 
abortion, the efficacy of single dose 800 μg misoprostol is evaluated. 
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 MISOPROSTOL PHARMACOLOGY 
Drug Pharmacology 
Misoprostol:  
PGE1 orally active analogue contain equal amounts of two 
diastereomers presented below with their enantiomers indicated by 
(±) 
Molecular formula   :  C22 H38 O5
Clinical Pharmacology: 
Pharmacokinetics:  
Misoprostol is extensively absorbed both orally, vaginally, 
undergoes rapid de esterification, to its free acid – misoprostolic acid 
which is responsible for its clinical activity, and unlike the parent 
compound, is detectable in plasma. The ‘alpha’ side chain undergoes 
beta oxidization and beta side chain undergoes Omega Oxidation 
followed by reduction of ketone to give Prostaglandin F analogs 
Tmax: 12+3 min (1/2 life 20-40 min.) Sr. Protein binding is 
less than 90%. 
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Mechanism of Action: 
Misoprostol is a myometrial stimulant which binds to E-2 and 
E-3 prostanoid receptors. Its active plasma metabolite is 
misoprostolic acid. It is rapidly absorbed after oral, vaginal and 
rectal administration. With oral administration the half life is less 
than 30 minutes, and peak level is at 15 minutes. After vaginal 
administration, there is a gradual rise to a maximum level at 60-120 
minutes, but at 240 minutes (4 hours) the level is still at 60 percent 
of peak level. 
Effects:  
(a) GIT effects  
PGE1, analogue, gastric anti secretory agent with 
protective effects on the gastroduodenal mucosa. The drug 
inhibits gastric acid secretion and protects mucosa from the 
NSAIDS. 
(b) Genito Urinary &renal effects:  
Misoprostol has been reported to increase the amplitude and 
frequency of uterine contractions and to produce stimulate 
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uterine bleeding and total or partial expulsion of uterine 
contents in pregnant women. 
(c)      Endocrine & Gonadal effects:  
Misoprostol does not appear to have clinically important 
effects on serum levels of circulating prolactin, thyrotropin, 
somatotropin, thyroxine, FSH, LH, SHBG, Progesterone, 
testosterone, estradiol (or) gonadotropins. In some patients it 
increases serum cortisol concentration.  
(d) Ocular:  
Though no effect on ocular system is recorded, in some 
isolated cases reports of conjunctivitis is documented with 
misoprostol use.  
(e) Hepatic effects:  
Some studies suggest that there is elevated hepatic enzyme 
levels after their usage. 
(f) Respiratory effects:   
Though no major effects on respiratory system with 
Misoprostol usage were reported, rare incidence of upper 
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respiratory tract infection, bronchitis, bronchospasm, dyspnea, 
pneumonia, epistaxis are reported in few studies. 
(g) Immunological effects:  
Very rare development of anaphylaxis with misoprostol use 
is also recorded.  
(h) Other effects:  
Misoprostol have no effect on cell or humoral mediated 
immune response and does not affect platelet aggregation, or 
produce clinically important cardiovascular or respiratory 
changes.   
Few studies show the occurrence of deafness, tinnitus, ear 
ache in patients using misoprostol. 
Adverse effects  
(a) GIT:  
Diarrhoea (15-40%) and abdominal pain (13-20%) are 
common side effects with misoprostol usage. Diarrhoea is dose 
related and early to occur,  hence should be avoided along with 
magnesium containing acids during misoprostol usage. 
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(b) Gynecological: 
Women who received misoprostol during clinical trials 
reported the following gynecological disorders: 
 Spotting (0.7%) 
 Cramps (0.6%) 
 Hypermenorrhoea (0.5%), 
 Menstrual disorder (0.3%) and 
 Dysmenorrhoea (0.1%). 
(c) Skin: 
There are also few adverse effects like rashes, dermatitis, 
alopecia, Pallor, and breast pain are also noted in few patients. 
(d) Special senses: 
Few cases also reported with abnormal taste, abnormal 
vision, conjunctivitis, deafness, tinnitus, ear ache as per some 
studies.  
(e) Musculoskeletal: 
Dermatitis, alopecia, pallor, musculoskeletal effects, 
arthralgia, myalgia, muscle changes, muscular and stiffness, back 
pain are also reported in some cases. 
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(f) CVS 
Very few cases are reported infrequently with chest pain, 
edema, diaphoresis, hypertension, hypotension, arrhythmia 
increases in cardiac enzymes and syncope.  
Others 
In some clinical trials following adverse reactions were  
reported in more than 1% of the subjects. 
They are, 
 Nausea (3.2%) 
 Flatulence (2.9%) 
 Headache (2.4%) 
 Dypepsia (2.0%) 
 Vomiting (1.3%) and  
 Constipation (1.1%) 
Over dosage: 
Cumulative total daily dose of 1600 mcg have been 
tolerated with minimal gastrointestinal discomfort. 
Misoprostol is metabolized like a fatty acid. 
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 Advantages of vaginal misoprostol over oral administration 
 
1. Vaginal dose can be increased without much side 
effects. So, it makes the drug very useful for 
termination in later  gestations also. 
2. Vaginal Misoprostol increases the rate of complete 
abortion as shown by –E1 Relary et al and then 
Ashoketal and Schatt et al studies. Incidence of 
vomiting and diarrhea were significantly lower in 
vaginal users, which was supported by Zieman et al in 
his study. 
3. Longer and sustained blood levels after vaginal 
administration are maintained. 
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Comparative Effectiveness of Vaginal and oral 
Administration of Misoprostol 
Oral Vaginal 
 Side effects : more 
 More dosage needed for 
the same gestations. 
 Undergoes presystemic 
gastrointestinal and 
hepatic metabolism 
 Bioavailability is less. 
 
 87% of success. 
 7% failure 
 abortion with 4hrs -78%. 
 
 Side effects: less 
 Less dosage needed for 
the same gestations 
 Bypasses presystemic 
gastrointestinal and 
hepatic metabolism  
 Bioavailability is 3 
times more than oral 
 95% of success  
 1% failure 
 abortion within 4 hrs -
93% 
 
Supported by EL Refaey et al 1995 
Various dosage regimens used in abortion are 
 200 mcg every 4 hrs. 
 400 mcg every 6 hrs. 
 600 mcg every 12 hrs. 
 800 mcg every 24 hrs. 
 800 mcg every 12 hrs 
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MATERIALS AND METHODS 
 This study was carried out in the Department of Obstetrics and 
Gynaecology, Government Rajaji Hospital, Madurai during the 
period of February 2007 to July 2007. 
 The purpose of the study was to evaluate the efficacy of single 
dose 800 μg of vaginal misoprostol in I trimester pregnancy 
termination. 
Patient’s Selection Criteria : 
 50 patients with intra uterine pregnancy up to 12 weeks were 
randomly selected for the study. 
 The age group was between 20 to 34 years 
 Patient with scarred cervix, previous cervical surgery and 
previous scar in the uterus and with medical or surgical disease were 
excluded from the study. 
Patient informed consent : 
 Written consent of the patients were taken and if the patient 
was a minor her parents consent was obtained. Patient was given 
prophylactic antibiotics. 
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Preparation of the patients : 
 After patient got admitted, complete history was taken 
 General examination and systemic examination was carried 
out. 
 A speculum and vaginal examination was done in all cases. 
 Patients were counselled regarding the method and side effects 
of the drug. 
Investigations : 
 Urine Alb 
   Sugar 
   Dep 
 Haemoglobin 
 Haematocrit 
 Blood grouping and Rh typing 
 Bleeding time 
 Clotting time 
 Ultrasonogram 
 
 
 48
Preparation of patients : 
 The procedures and methodology was explained to the patients 
and they were asked to empty the bladder just before the procedure. 
 The patient was placed in lithotomy position 
 No anaesthesia was given. 
Methodology : 
 Under aseptic precaution after putting in a speculum, posterior 
lip of the cervix was visualized and 800 μg of misoprostol soaked in 
normal saline was kept in the posterior fornix and the patient was 
instructed to stay in bed for 30 min. 
 Time of application of tablets was noted. Patient was carefully 
monitored for development of symptoms like 
 Nausea 
 Vomiting 
 Bleeding 
 Abdominal pain 
  Patient was monitored for complete expulsion of products 
of conception for 12 hours and if it does not occur 2nd dose of 800ug 
misoprostol was kept in posterior fornix.  
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 Four hours later patient underwent USG examination to 
confirm the completeness of expulsion of product of conception. 
 Haemoglobin and hematocrit were checked after 48 hrs. 
 Coagulation profile also rechecked after expulsion. 
Follow up : 
 Patient was advised to come for the follow up at the end of one 
month and at the end of 3 months to enquire about the cyclic 
regularity and the general status 
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 ANALYSIS OF STUDY 
50 CASES 
Analysis was done in the following aspects 
¾ Distribution of age 
¾ Gestational age 
¾ Parity 
¾ Socio economic status 
¾ Induction, abortion interval 
¾ Requiring 2nd dose and curettage 
¾ Changes in Hb / PCV after expulsion 
¾ Various side effects 
¾ Success rate 
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RESULTS 
 
 
Table 1  
 Age Distribution 
Cases Age in years 
No % 
Less than 20 4 8 
21 – 24 22 44 
25 – 29 17 34 
30 – 34 4 8 
35 & above 3 6 
Total 50 100 
Mean 
S.D 
24.86 
4.9 
 
44% (22/50) of the patients were in the age group of 21-24 
years 
34% (17/50) were in the age group was 25-29 years 
8% (4/50) were in the age group of 30-34 years 
6% (3/50) were above 35 years of age. 
 52
 Table - 2 
Gestational age 
 
Cases Gestational  
Age in weeks No % 
< 8 17 34 
9 – 10 19 38 
11 – 12 14 28 
Total 50 100 
Mean 
S.D 
9.7 weeks 
1.56 
 
In 34% (17/50) of patients the gestational age was < 8 weeks 
In 38% (19/50) of patients the gestational age was 9 to 10 weeks 
In 28% (14/50) of patients the gestational age was 11 to 12 weeks 
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Table - 3  
 Parity 
 
Cases Parity 
No % 
Primi 25 50 
Multi 25 50 
 
 50% (25/50) were primi para 
 50% (25/50) were multi para
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Table - 4 
Socio – economic status 
 
Cases Socio – economic 
status No % 
Less than IV - - 
IV 27  54 
V 23 46 
More than V - - 
Total 50 100 
 
All the cases belong to the lower economic strata of the 
society
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Table - 5 
Induction Abortion Interval 
Cases IAI in hours 
No % 
Less than 5 - - 
6 – 10 24 58 
11 – 15 10 20 
16 – 20 9 18 
More than 20 2 4 
Total 50 100 
Mean 
S.D 
11.38 minutes 
4.61 
 
In 58% (24/50) of patients the induction abortion interval was 6 
to 10 hours. 
In 20% (10/50) of patients the induction abortion interval was 
11to15 hours. 
 In 18% (9/50) of patients the induction abortion interval was 
16 to 20 hours. 
 Only in 4%(2/50) of patients the induction abortion interval 
exceeded 20 hours. 
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 Table - 6 
Efficacy 
 
Cases Cases requiring 
No % 
Single dose only 37 74 
Second dose 9 18 
Curettage 4 8 
Total 50 100 
 
  Success rate = 70% 
 
74% (37/50)of the patients had a complete expulsion with 
single dose of 800 ug of vaginal misoprostol 
18%(9/50) required a second dose after 12 hours. 
8% (4/50) of the patients required a check curettage
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Table - 7 
Changes in haemoglobin 
 
Hb Mean S.D 
Before expulsion 9.73 0.84 
After expulsion 9.59 0.86 
Change -0.14 0.11 
 
The mean Hb of the patients before expulsion was 9.73 
gm % 
The mean Hb of the patients after expulsion was 9.59 
gm% 
  There is no statistically significant difference in Hb after 
expulsion.
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Table 8 
Changes in Packed cell volume 
 
PCV Mean S.D 
At induction 28.48 3.63 
After expulsion 28.14 3.47 
Change -0.34 0.21 
 
The mean PCV of the patients at induction was 28.48 
The mean PCV of the patients after expulsion was 28.14 
There is no statistically significant difference in PCV 
after expulsion 
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Table - 9 
Complication 
 
Cases Complications 
No % 
a) Present 
  Vomiting 
   Diarrhoea 
  Total 
 
3 
6 
9 
 
6 
12 
18 
b) Absent 41 82 
 
6% (3/50) of the patients had vomiting, 
 12% (6/50) of the patients had diarrhea 
Hence, 18% (9/50) of the patients had minor side effects.
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Statistical Tools ( To be included at the end of Materials and 
Methods) 
  
The information collected regarding all the selected cases were 
recorded in a Master Chart. Data analysis was done with the help of 
computer using Epidemiological Information Package (EPI 2002). 
  
Using this software, frequencies, percentage, mean and 
standard deviations were calculated.  
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DISCUSSION 
 
 Cervical ripening and uterotonic effects of prostaglandin 
(PGE1 analogue – Misoprostol) is effectively utilized in this study 
for non invasive expulsion of products of conception. 
Age : 
 In this study, 44%(22/50) of the patients were between age 
group of 21-24.  34%(17/50) of the patients were in the age group of 
25-29 years.  The youngest was 19 years and eldest was 39 years. 
This study correlates with randomized control trial conducted by 
Salkos et al, Department of Obstetrics and Gynaecology, University 
of Athens, Aretacit Hospital, Greece, Dec. 2005 in which 80% of the 
patients were in the age group of 21-30 years.  
Period of Gestation : 
 In our study 38%(19/50) of the patients were in the gestational 
age of 9-10 weeks. 
 34% (17/50) 1of the patients were on the gestational age < 8 
weeks, hence majority of the patients gestational age was upto 10 
weeks. 
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 This study correlates with the prospective study conducted by  
Carbowell JL et al, Hospital Docante giveeco – Obstetric Evsebio 
hermandis (maternidad obrena) ginded de lathabama Cuba, March 
1995 in which 90% of the patients gestational age was < 10 weeks. 
Parity : 
 50%  of the patients were primi gravida and 50% were 
multigravida. 
 The induction abortion interval was not affected by parity. 
 According to the study by Herabutya Y, O- Prasertsawat P, et 
al Thailand – 1997.  Success of abortion was unaffected by parity. 
 
Induction abortion interval : 
 In our study, the mean induction abortion interval was 11.38 
hrs. 
 The study correlates with the prospective study conducted by 
Salakar et al. Department of Obstetrics and Gynaecology University 
of Athens, Aretaiein, Hospital Greece, 2005 involving a group of 
162 volunteers.  The mean expulsion time interval was 8.5+ 4.0 hrs. 
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 Success rate : 
 Failure of procedure is defined as failure of expulsion in 12 hrs 
with single dose of 800 ug of vaginal misoprostol. 
 In our study, 74% of patients (37/50) had a complete expulsion 
of products of conception in single dose of 800 ug of vaginal 
misoprostol.   
 4 cases  who had incomplete expulsion required  a curettage  
after the first dose as they had profuse bleeding per vaginal. 
 9 cases needed a second dose of 800 ug of vaginal misoprostol 
 This study correlates with the prospective study conducted by 
Kovavisarach. F. Jamman sinic 2005, Department of Obstetrics and 
Gynaecology, Rajavithi Hospital, Ministry of public health, 
Bangkok.  They showed 78.4% of patients had complete expulsion 
of products of conception. 
Changes in Haemoglobin and PCV : 
 In our study, the hemoglobin decreased by a mean of 0.14 and 
PCV decreased by a mean of 0.34. 
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 None of the patients required any blood transfusion for 
reduction in Hb%.  This indicates that blood loss is minimum with 
this method. 
 This study correlates with the study done by Thomas betry, 
Habeebnillah et al JOG Ind. Vol 54 with their mean fall of Hb being 
0.4 gm % 
Complications : 
 Out of the 50 patients,  9 patients had minor side effects for 
misoprostol, 3 patients had vomiting and 6 patients had diarrhea. 
 No major effects was noted in our study which was very much 
comparable with the study done by Feldman DA et al and herabutya 
H et al.  They showed no additional side effects with 800 ug of 
misoprostol. 
Post expulsion USG : 
 All 50 patients underwent ultrasound examination after 4 hours 
of expulsion and in 92%(46/50) of the  patients  their uterine cavity 
was found empty. 
 8% (4/50) patients revealed bits of conceptus and they 
underwent curettage. 
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Follow up : 
 All cases were followed up for cycle regularity and other side 
effects like continuous spotting, any profuse white discharge 
suggestive of infection and general status of the patient.  None of the 
patients had the above said symptoms. 
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SUMMARY 
 This study was conducted in the Department of Obstetrics and 
Gynaecology, Government Rajaji Hospital, Madurai between the period 
of Feb 2007 to July 2007. 
 50 patients underwent this study. 
 In this study, 78%(39/50) of the patients were between age group of 
21-29 years. 
 50%(25/50) were primi gravida and 50%(25/50) were multigravida. 
Success rate were unaffected by parity. 
 Majority of the patients were in the gestational age of < 10 weeks 
 74% of the patients had complete expulsion of products of 
conception with single dose of 800 ug of vaginal misoprostol  
 8% of the patients required curettage of the uterine cavity. 
 18% of the patients required a second dose of 800 ug of vaginal 
misoprostol. 
 The mean  induction abortion interval was 11.38 hrs. 
 Out of 50 cases 9 had minor side effects like vomiting and diarrhea. 
 Hence single dose of vaginal misoprostol (800ug) is found to be 
effective in I trimester pregnancy termination with minimal side effects. 
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CONCLUSION 
 
 Vaginal prostaglandin E1 analogue (misoprostol) is a very 
safe and effective method of termination of I trimester pregnancy 
 Single high dose of vaginal misoprostol ( 800ug) is found 
to be effective in I trimester pregnancy termination with minimal 
side effects and shorter duration abortion interval and hospital 
stay. 
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PROFORMA 
Name :      Age : 
IP.No.  :     Unit : 
Address  : 
Socio economic class : I     II  III  IV      V 
Parity   : Primi   Multi 
Period of Pregnancy : 
Whether any medical disease 
Associated with pregnancy   :DM / HT / Heart Disease / hepatic /Renal 
 
Ultra sonogram findings :  
Coagulation Profile  : 
Hb & HCT before induction with misoprostol : 
Hb & HCT 48 hours after expulsion 
Date of application of misoprostol 
Time of first vaginal application of misoprostol 
Initial Dosage 
No.of doses applied 
Date of expulsion 
Time of expulsion 
Induction expulsion interval  : 
USG after expulsion  : Complete    Incomplete 
Whether patient 
Underwent curettage later :  
Side effects    : Vomiting   Diarrhoea 
Follow up after 1 month  : 
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ABBREVIATIONS 
 
 SCC - SOCIO ECONOMIC CLASS 
 I A I - INDUCTION ABORTION INTERVAL 
 Y - YES 
 D - DIARRHOEA 
 V - VOMITING 
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